Click here to read the Cover Story, "Specialists look positively at complex, dynamic landscape of wet AMD."
Anti-VEGF agents have transformed retinal disease management.
However, the benefit of anti-VEGF therapy is still limited by the higher cost of treatment, specifically in the areas of the world where patients are not well covered with insurance and need to pay from their pocket.
Off-label bevacizumab usage has been associated with the risk for infection due to a lack of compounding pharmacies in such areas. The entry of biosimilars to Lucentis (ranibizumab, Genentech) in India has made a